-
公开(公告)号：US11987633B2
公开(公告)日：2024-05-21
申请号：US17204166
申请日：2021-03-17
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
CPC分类号： C07K16/2863 , C07K16/2803 , C07K16/2878 , C07K16/2884 , C07K2317/31 , C07K2317/34
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
-
公开(公告)号：US11926666B2
公开(公告)日：2024-03-12
申请号：US17306051
申请日：2021-05-03
发明人： Bertram Weiss , Anna-Lena Frisk , Ruprecht Zierz , Peter Kufer , Tobias Raum , Doris Rau , Jonas Anlahr , Ralf Lutterbüse , Lisa Nahrwold , Christoph Dahlhoff , Claudia Blümel , Patrick Hoffmann
CPC分类号： C07K16/2809 , A61P35/00 , C07K16/28 , C07K16/3053 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US20230272113A1
公开(公告)日：2023-08-31
申请号：US17813434
申请日：2022-07-19
发明人： Tobias Raum , Claudia Blümel , Franziska Bott , Christoph Dahlhoff , Patrick Hoffmann , Elisabeth Nahrwold , Jochen Pendzialek
CPC分类号： C07K16/40 , C07K16/2809 , C07K16/2863 , C07K2317/31 , C07K2317/64 , C07K2317/33 , C07K2319/31 , C07K2317/76 , C07K2317/94 , C07K2317/73 , C07K2317/92 , C07K2317/622 , C07K2317/56
摘要： The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human FLT3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US20230192884A1
公开(公告)日：2023-06-22
申请号：US17812061
申请日：2022-07-12
发明人： Tobias Raum , Markus Münz , Johannes Brozy , Peter Kufer , Patrick Hoffmann , Matthias Friedrich , Benno Rattel , Pamela Bogner , Andreas Wolf , Cornelius Pompe
IPC分类号： C07K16/30 , C07K16/28 , A61K39/395 , C07K16/46
CPC分类号： C07K16/30 , C07K16/2863 , C07K16/2803 , C07K16/3053 , C07K16/2875 , C07K16/2887 , A61K39/39558 , C07K16/28 , C07K16/2809 , C07K16/468 , C07K2317/33 , C07K2319/00 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/64 , C07K2317/94
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3cε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20200048357A1
公开(公告)日：2020-02-13
申请号：US16373083
申请日：2019-04-02
发明人： Tobias Raum , Markus Münz , Johannes Brozy , Peter Kufer , Patrick Hoffmann , Matthias Friedrich , Benno Rattel , Pamela Bogner , Andreas Wolf , Cornelius Pompe
IPC分类号： C07K16/28 , A61K39/395 , C12N5/16 , C12N15/63
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20190263907A1
公开(公告)日：2019-08-29
申请号：US16291826
申请日：2019-03-04
发明人： Tobias Raum , Claudia Blümel , Christoph Dahlhoff , Patrick Hoffmann , Peter Kufer , Ralf Lutterbüse , Elisabeth Nahrwold , Jochen Pendzialek
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , A61K39/00
摘要： The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US10301391B2
公开(公告)日：2019-05-28
申请号：US15422619
申请日：2017-02-02
发明人： Tobias Raum , Markus Münz , Johannes Brozy , Peter Kufer , Patrick Hoffmann , Matthias Friedrich , Benno Rattel , Pamela Bogner , Andreas Wolf , Cornelius Pompe
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20170275373A1
公开(公告)日：2017-09-28
申请号：US15329668
申请日：2015-07-31
发明人： Peter Kufer , Patrick Hoffmann , Markus Münz , Matthias Klinger , Elaine-Pashupati Dopfer , Elisabeth Nahrwold
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2319/31
摘要： The present invention provides to a bispecific single chain antibody construct binding to a target cell surface antigen via a first binding domain and to the T cell surface antigen CD3 via a second binding domain, the construct comprising two FcRn binding peptides. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
-
公开(公告)号：US20170218078A1
公开(公告)日：2017-08-03
申请号：US15422647
申请日：2017-02-02
发明人： Tobias Raum , Markus Münz , Johannes Brozy , Peter Kufer , Patrick Hoffmann , Matthias Friedrich , Benno Rattel , Pamela Bogner , Andreas Wolf , Cornelius Pompe
CPC分类号： C07K16/30 , C07K16/28 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2875 , C07K16/2887 , C07K16/3053 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/64 , C07K2317/94 , C07K2319/00
摘要： The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
公开(公告)号：US09688760B2
公开(公告)日：2017-06-27
申请号：US14176091
申请日：2014-02-08
发明人： Peter Kufer , Dirk Nagorsen , Juergen Scheele , Gerhard Zugmaier , Matthias Klinger , Patrick Hoffmann , Virginie Naegele , Elaine-Pashupati Dopfer
IPC分类号： C07H21/04 , C07C43/00 , C07C49/00 , C07C237/26 , C07C331/00 , C12P21/08 , A01N37/18 , A61K31/65 , A01N31/00 , A61K31/095 , G01N33/00 , C12N5/071 , C07K16/28 , A61K31/10 , A61K39/395 , C07K16/18 , G01N33/50 , A61K39/00
CPC分类号： C07K16/2809 , A61K31/10 , A61K31/65 , A61K39/3955 , C07K16/18 , C07K2317/70 , G01N33/5008 , G01N2500/04
摘要： The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment. Such anti-adhesive type compounds include, but are not limited to, antibodies, like natalizumab, efalizumab, and etrolizumab; minocycline, (acetyl-)salicyclic acid, astilbin, and flavonoids; and thrombin and pentosanpolysulfate (PPS), or a pharmaceutically acceptable salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
75 条记录 (耗时 0.067 秒)
